Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 DefiniGEN Licences Lung Stem Cell Technology from University of Cambridge | Contract Pharma

What are you searching for?

Sign in
Breaking News

DefiniGEN Licences Lung Stem Cell Technology from University of Cambridge

Plans are to develop cell products and services for drug discovery and the study of lung diseases

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

DefiniGEN Ltd., a provider of stem cell life science products and services, has strengthened its IP portfolio with a licence for cutting edge lung stem cell technology from the University of Cambridge. The technology will be used by DefiniGEN to develop new, optimized cell products and services for drug discovery and the study of lung diseases, including cystic fibrosis.

The technology, licensed to DefiniGEN by Cambridge Enterprise, the commercialization arm of the University of Cambridge uses induced pluripotent stem cells, or iPS cells, to recreate embryonic lung development in the lab by activating a process known as gastrulation, in which the cells form distinct layers, from which the lung grows. The technology enables these cells to develop further, into distal airway tissue. The distal airway is the part of the lung responsible for gas exchange and is often implicated in disease, such as cystic fibrosis, some forms of lung cancer and emphysema.

“This license enables us to use stem cells to grow highly functional lung cells on an industrial-scale for the first time,” said Marcus Yeo, chief executive officer, DefiniGEN. “These cell products can then help researchers to elucidate key mechanisms of disease and enable pharmaceutical companies to screen for potential drugs in a reproducible and cost-effective way.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics